To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Targeting CXCR1/2 Does No… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Targeting CXCR1/2 Does Not Improve Insulin Secretion After Pancreatic Islet Transplantation: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial in Type 1 Diabetes

Journal article
Authors P. Maffi
T. Lundgren
G. Tufveson
E. Rafael
J. A. M. Shaw
A. Liew
F. Saudek
P. Witkowski
K. Golab
F. Bertuzzi
Bengt Gustafsson
L. Daffonchio
P. A. Ruffini
L. Piemonti
R. Nano
A. Mercalli
V. Lampasona
P. Magistretti
V. Sordi
S. Antonio
B. Antonioli
M. Galuzzi
M. C. Tosca
L. De Carlis
G. Colussi
O. Korsgren
H. Pollard
Published in Diabetes Care
Volume 43
Issue 4
Pages 710-718
ISSN 0149-5992
Publication year 2020
Published at Institute of Neuroscience and Physiology, Department of Physiology
Pages 710-718
Language en
Keywords beta-cell function, antiinflammatory strategies, inhibition, induction, immunosuppression, engraftment, survival, regimen, Endocrinology & Metabolism
Subject categories Endocrinology and Diabetes


OBJECTIVE Reparixin is an inhibitor of CXCR1/2 chemokine receptor shown to be an effective anti-inflammatory adjuvant in a pilot clinical trial in allotransplant recipients. RESEARCH DESIGN AND METHODS A phase 3, multicenter, randomized, double-blind, parallel-assignment study () was conducted in recipients of islet allotransplants randomized (2:1) to reparixin or placebo in addition to immunosuppression. Primary outcome was the area under the curve (AUC) for C-peptide during the mixed-meal tolerance test at day 75 +/- 5 after the first and day 365 +/- 14 after the last transplant. Secondary end points included insulin independence and standard measures of glycemic control. RESULTS The intention-to-treat analysis did not show a significant difference in C-peptide AUC at both day 75 (27 on reparixin vs. 18 on placebo, P = 0.99) and day 365 (24 on reparixin vs. 15 on placebo, P = 0.71). There was no statistically significant difference between treatment groups at any time point for any secondary variable. Analysis of patient subsets showed a trend for a higher percentage of subjects retaining insulin independence for 1 year after a single islet infusion in patients receiving reparixin as compared with patients receiving placebo (26.7% vs. 0%, P = 0.09) when antithymocyte globulin was used as induction immunosuppression. CONCLUSIONS In this first double-blind randomized trial, islet transplantation data obtained with reparixin do not support a role of CXCR1/2 inhibition in preventing islet inflammation-mediated damage.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?